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Introduction
The World Health Organization (WHO) has 
established guidelines suggesting that levels 
of arsenic (As) in drinking water should 
not exceed 10 μg/L (WHO 1993). Several 
countries including the United States, India, 
Taiwan, Vietnam, and Japan have adopted 
the WHO’s guidelines in the establishment 
of their maximum contaminant levels (MCL) 
for As in drinking water, yet others have a 
higher MCL including Mexico at 25 μg As/L 
and Bangladesh at 50 μg As/L (Chen and 
Chiou 2011; Secretaría de Salud–Estados 
Unidos Mexicanos 2000; Nordstrom 2002). 
Even with these guidelines in place, there 
are currently millions of people worldwide 
who are drinking water with levels of As that 
greatly exceed the WHO standard or national 
standards (Centeno et al. 2007; Uddin and 
Huda 2011).
Exposure to elevated levels of inorganic 
arsenic (iAs) in drinking water is a major 
public health concern because iAs has 
been linked with numerous adverse health 
outcomes (Kapaj et al. 2006; Rahman M 
et al. 2009). The detrimental effects from 
long-term exposure include skin lesions, 
cardiovascular disease, peripheral vascular 
disease, diabetes mellitus, and cancers of the 
urinary bladder, skin, lung, liver, and prostate 
(Del Razo et al. 2011; International Agency 
for Research on Cancer 2004; Maull et al. 
2012; Rahman M et al. 2009; Tseng 2007b). 
It is also evident that certain populations, 
including pregnant women and their unborn 
children, are particularly susceptible to the 
adverse effects of iAs exposure (Vahter 2009). 
For instance, prenatal iAs exposure has been 
associated with a greater risk of adverse preg-
nancy outcomes such as preterm birth, low 
birth weight, and/or fetal loss (reviewed by 
Vahter 2009). In addition, exposure to high 
levels of iAs in utero or in early childhood 
has been associated with multiple adverse 
health outcomes, including both cancer and 
noncancer end points, later in life (Smith 
et al. 2006). The biological mechanisms that 
determine the nature and severity of adverse 
effects in iAs-exposed populations involve 
multiple factors such as the dose and duration 
of iAs exposure, efficiency of iAs metabolism, 
genetic background, nutritional status, and 
coexposure to other toxicants (Gebel 2000; 
Kapaj et al. 2006; Vahter and Concha 2001).
Along with life stage at time of exposure, 
the efficiency of iAs metabolism is a well-
documented risk factor for the development 
of several iAs-associated diseases (reviewed 
by Tseng 2007a). In humans, iAs has a 
biological half-life of approximately 24 hr 
(Buchet et al. 1981) and is metabolized to 
produce monomethylated and dimethyl-
ated arsenicals (MMAs and DMAs, respec-
tively). Six major arsenicals associated with 
iAs exposure and metabolism have been 
detected in human urine, namely arsenite 
(iAsIII), arsenate (iAsV), monomethylarsonous 
acid (MMAIII), monomethylarsonic acid 
(MMAV), dimethylarsinous acid (DMAIII), 
and dimethylarsinic acid (DMAV) (Thomas 
et al. 2001; Vahter 2002). Generally, total 
urinary arsenic in iAs-exposed individuals 
is composed of 10–20% total (trivalent 
+ pentavalent) iAs, 10–20% total MMAs, 
and 60–80% total DMAs (Vahter 1999, 
2002). In contrast to iAs, organic arsenicals 
such as arsenobetaine, arsenocholine, and 
arsenosugars are derived from food sources, 
primarily seafood (Choi et al. 2010). Because 
arsenosugars can be metabolized to DMAs, 
the presence of DMAs in urine may reflect 
exposure to both iAs and organic arsenic 
compounds (Choi et al. 2010). High urinary 
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Background: Exposure to inorganic arsenic (iAs) from drinking water is a global public health 
problem, yet much remains unknown about the extent of exposure in susceptible populations.
oBjectives: We aimed to establish the Biomarkers of Exposure to ARsenic (BEAR) prospective 
pregnancy cohort in Gómez Palacio, Mexico, to better understand the effects of iAs exposure on 
pregnant women and their children.
Methods: Two hundred pregnant women were recruited for this study. Concentrations of iAs in 
drinking water (DW-iAs) and maternal urinary concentrations of iAs and its monomethylated and 
dimethylated metabolites (MMAs and DMAs, respectively) were determined. Birth outcomes were 
analyzed for their relationship to DW-iAs and to the concentrations and proportions of maternal 
urinary arsenicals.
results: DW-iAs for the study subjects ranged from < 0.5 to 236 μg As/L. More than half of 
the women (53%) had DW-iAs that exceeded the World Health Organization’s recommended 
guideline of 10 μg As/L. DW-iAs was significantly associated with the sum of the urinary arsenicals 
(U-tAs). Maternal urinary concentrations of MMAs were negatively associated with newborn birth 
weight and gestational age. Maternal urinary concentrations of iAs were associated with lower mean 
gestational age and newborn length.
conclusions: Biomonitoring results demonstrate that pregnant women in Gómez Palacio are 
exposed to potentially harmful levels of DW-iAs. The data support a relationship between iAs 
metabolism in pregnant women and adverse birth outcomes. The results underscore the risks associ-
ated with iAs exposure in vulnerable populations.
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proportions of MMAs and high ratios of 
MMAs/DMAs, which are thought to be indi-
cators of an inefficient methylation of iAs, 
have been associated with the development of 
several adverse outcomes in humans including 
urinary bladder cancer, non-melanoma skin 
cancers, carotid atherosclerosis, and chromo-
somal aberrations (reviewed by Tseng 2007a). 
It is known that pregnancy can alter the 
metabolism efficiency of iAs (Gardner et al. 
2012; Hopenhayn et al. 2003b). However, 
the impact of this altered metabolism on 
pregnant women’s or children’s health is not 
well established.
We set out to understand the effects of 
iAs exposure and iAs metabolism during 
pregnancy on maternal/fetal health, with 
the ultimate aim of increasing awareness 
and reducing exposures to iAs. To this end, 
we established the Biomarkers of Exposure 
to ARsenic (BEAR) prospective pregnancy 
cohort. Women recruited to participate in the 
BEAR project reside in the Gómez Palacio 
area, which is located in the state of Durango 
in the Lagunera region of Northern Mexico. 
It is believed that > 450,000 people are 
exposed to levels of iAs in drinking water that 
exceed 50 μg/L in Mexico, including residents 
of Lagunera and Durango (Bundschuh et al. 
2012). Multiple adverse health outcomes 
have been associated with high iAs exposure 
in Lagunera, including skin lesions (Del Razo 
et al. 1997) and diabetes mellitus (Del Razo 
et al. 2011). The effects of iAs exposure on 
pregnant women and their newborn children 
have not been studied in this region. In this 
study we investigated the association between 
iAs exposure during pregnancy, iAs metabo-
lism efficiency, and birth outcomes in Gómez 
Palacio, Mexico.
Methods
Study design. BEAR participants, adult 
women, were recruited during the time 
frame of August 2011 through March 2012 
at the General Hospital of Gómez Palacio. 
Recruitment took place before delivery, 
usually within 24 hr of birth. The mean 
gestational age at birth was 39 weeks (range, 
34–42 weeks). All procedures associated with 
this study were approved by the institutional 
review boards of Universidad Juarez del 
Estado de Durango (UJED), Gómez Palacio, 
Durango, Mexico, and the University of 
North Carolina at Chapel Hill (UNC-Chapel 
Hill). For each woman participation require-
ments at the time of recruitment included 
a) 1 year minimum residence in the Gómez 
Palacio region, which included urban loca-
tions of Gómez Palacio and surrounding rural 
locations, b) confirmation of a pregnancy 
without complications such as eclampsia or 
preeclampsia, and c) good overall health status 
(i.e., no signs of chronic or acute disease). 
A total of 221 women were approached for 
the study. Of those, 93% (n = 206) provided 
informed consent for participation in the 
study. Six women were not included in the 
study as a result of confirmation of a twin 
pregnancy (n = 1; 0.5%) or sample collec-
tion failure (n = 5; 2.4%). A social worker 
administered questionnaires to the study 
participants to collect the following informa-
tion: age, education, occupation, time living 
at residence, smoking status and alcoholic 
beverage consumption during pregnancy 
(both defined as yes or no and frequency), 
daily prenatal supplement intake (yes or no), 
residence location (urban or rural), seafood 
consumption (yes or no), source and daily 
consumption of drinking and cooking water, 
and source of bathing water. In addition, 
information on previous pregnancy outcomes 
including number of pregnancies and number 
of previous pregnancy losses was gathered 
from questionnaires. Information on birth 
outcomes/measures including newborn 
birth weight, newborn length, gestational 
age, head circumference, placental weight, 
and 5-min Appearance, Pulse, Grimace, 
Activity, Respiration (APGAR) score was 
gathered at time of delivery by the physi-
cian (Montgomery 2000). Data on adverse 
outcomes were collected, including preterm 
birth (gestational age < 37 weeks), low birth 
weight (LBW; < 2,500 g), small for gesta-
tional age (SGA; birth weight < 10th percen-
tile), and large for gestational age (LGA; 
birth weight > 90th percentile). SGA and 
LGA categories were based on newborn data 
collected from northern regions of Mexico 
(Montes-Núñez et al. 2011; Rios et al. 2008).
Sample collection. Within 4 weeks of 
newborn delivery, a drinking-water sample 
was collected by the research team at the 
homes of each of the study participants. 
Drinking-water samples were collected based 
on the subjects’ primary drinking-water 
source (i.e., tap or bottled water). Maternal 
spot urine samples were collected at the 
hospital before birth, immediately transferred 
to cryovials, and placed in liquid nitrogen. 
Aliquots of urine samples were shipped on 
dry ice to UNC-Chapel Hill and immedi-
ately stored at –80°C. It was not possible 
to inform the women of the levels of iAs in 
their drinking water during their pregnan-
cies because these results were not available 
before the birth of their children. However, 
the women were informed within 3 months 
of delivery.
Detection of arsenic in drinking water 
and urine. The concentrations of iAs in 
drinking water (micrograms As/L; DW-iAs) 
were measured at UJED, Mexico, using 
hydride generation–atomic absorption 
spectrometry (HG-AAS) supported by a 
FIAS-100 flow injection accessory system 
as described previously (Devesa et al. 2004; 
Le and Ma 1998). The Trace Elements in 
Water standard reference material (SRM 
1643e) (National Institute of Standards and 
Technology, Gaithersburg, MD) was used for 
quality control. The limit of detection (LOD) 
for iAs in drinking water by HG-AAS was 
0.46 μg As/L.
All urine analyses were conducted at 
UNC-Chapel Hill. Because of the capacity of 
trivalent arsenicals to oxidize to pentavalent 
forms in urine, the accurate measurements 
of urinary iAsIII, MMAIII, and DMAIII were 
not possible after transport to UNC-Chapel 
Hill (Valenzuela et al. 2005). Concentrations 
of U-iAs, U-MMAs, and U-DMAs were 
determined by HG-AAS with cryotrap-
ping (Devesa et al. 2004; Hernández-Zavala 
et al. 2008, 2009). Five-point calibration 
curves were prepared using pentavalent iAs, 
MMAs, DMAs standards (> 98% pure) as 
described previously (Hernández-Zavala et al. 
2008), and the SRM 2669 Arsenic Species 
in Frozen Human Urine (National Institute 
of Standards and Technology) was used for 
quality control (Del Razo et al. 2011). The 
LODs for U-iAs, U-MMAs, and U-DMAs 
were 0.2, 0.1, and 0.1 μg As/L, respectively.
The specific gravity (SG) of each urine 
sample was measured using a handheld 
refractometer (Reichert TX 400 #13740000; 
Reichert Inc., Depew, NY). To account for 
differences in water intake/differential hydra-
tion, concentrations of U-iAs, U-MMAs, and 
U-DMAs in each urine sample were adjusted 
using the following equation: iAs × (mean 
SG – 1)/(individual SG – 1) as previously 
described (Nermell et al. 2008; Yassine et al. 
2012). Urinary concentrations of U-tAs (sum 
of iAs, MMAs, DMAs) were reported as 
SG-adjusted values (micrograms As/L urine).
Statistical analysis. Data were analyzed 
using the statistical package SAS 9.3 (SAS 
Institute Inc., Cary, NC). Arsenical concen-
trations in drinking water and urine that were 
below their respective LODs were assigned a 
value equal to the LOD divided by the square 
root of 2. To determine the efficiency of iAs 
metabolism, the proportion of total urinary 
As comprising the individual arsenicals iAs, 
MMAs, and DMAs (e.g., metabolism indica-
tors) was calculated for each study subject. 
A Spearman rank correlation was calcu-
lated to quantify the relationship between 
DW-iAs and U-tAs.
Differences in DW-iAs were analyzed 
based on maternal characteristics (i.e., reported 
drinking- and cooking-water source as tap or 
bottle, reported seafood consumption, location 
of residence, and maternal smoking status 
and alcohol consumption). The nonpara-
metric Wilcoxon rank sum test was used 
because of the failure of DW-iAs to achieve 
normality in transformations. Differences in 
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log-transformed U-tAs were analyzed based 
on maternal characteristics using Student’s 
two-sample t-test. Age- and education-based 
comparisons of levels of DW-iAs and U-tAS 
were analyzed using a Kruskal–Wallis test and 
analysis of variance, respectively.
We used multivariable adjusted regres-
sion models to assess the relationships 
between exposure or metabolism indicators 
(modeled as nontransformed, urinary SG–
adjusted, continuous variables) and birth 
outcomes (modeled as continuous variables). 
Regression assumptions of linearity and the 
homogeneity of residuals were evaluated by 
examination of appropriate residual plots. 
Covariates were selected if associated with 
both exposure and outcome or based on their 
a priori status as known confounders using a 
directed acyclic graph (DAG). Additionally, 
if covariates changed the estimate by at least 
10%, they were included in the model. 
Model 1 included the following covariates: 
maternal age at delivery (as a continuous 
variable), education level as a measure for 
socioeconomic status (SES) (< high school, 
high school, college, > college), smoking 
status (dichotomized as yes/no), and alcoholic 
beverage consumption during pregnancy 
(dichotomized as yes/no). Gestational age was 
not included in model 1 because of its poten-
tial role as a mediator of birth weight that 
can result in biased estimates (Wilcox et al. 
2011). Model 2 included gestational age as a 
covariate for comparative purposes. Model 3 
was run as part of a sensitivity analysis exam-
ining the effects of seafood consumption as 
a variation of model 1 that excluded seafood 
consumers. Regression results are presented 
as a change in birth outcomes/measures 
with a 1-unit change in exposure indicators 
or metabolism indicators. The relationships 
between covariates, exposure indicators, 
metabolism indicators, and sex of newborn 
were assessed using a Wilcoxon rank sum test. 
Statistical significance for all tests was set at 
an alpha of < 0.05.
Results
Maternal and newborn characteristics. 
All maternal and birth characteristics are 
presented in Table 1. Women in this cohort 
were relatively healthy and free of disease with 
no major adverse birth outcomes observed. 
All pregnancies resulted in a singleton live 
birth. The ages of the participants ranged 
from 18 to 41 years (mean, 24 years), and 
all were of Hispanic ethnicity. Of the study 
cohort, approximately 75% had at least a high 
school education, and all had lived in their 
current residence for at least 1 year (mean, 
20 years). Most women (97%) reported 
taking prenatal vitamins daily, and most 
women (78%) did not consume seafood 
during their pregnancy. For 35% of the 
women, the index pregnancy was their first 
pregnancy. A previous pregnancy loss was 
reported by 12% of all women. Among all 
pregnancies, 59% were delivered by vaginal 
delivery and 41% were delivered by cesarean 
section, a rate common in Mexico (Boyle and 
Reddy 2012).
The average gestational age of the 
newborns was 39 weeks. Of all births, 1.5% 
were preterm (< 37 weeks). Of the newborns, 
104 (52%) were male and 96 (48%) were 
female. The average weight of the newborns 
was 3,339 g (SD ± 500 g); males had a 
significantly (p = 0.0003) higher birth weight 
(3,453 g) relative to females (3,215 g). 
Among newborns, 2% were LBW, 14% were 
SGA, and ~ 10% were LGA. The average 
placental weight was 648 g. The newborns 
had an average crown to heel length of 50 cm, 
an average head circumference of 35 cm, and 
an average APGAR score of 9 (Table 1).
Levels of iAs in drinking-water and 
urinary samples. Levels of iAs in study 
subjects’ drinking water ranged from below 
the LOD (0.46 μg As/L) to 236.0 μg As/L 
(mean, 24.6 μg As/L) (Table 1). Of the 200 
women, 76% had detectable levels of iAs in 
drinking water. In total, 107 drinking-water 
samples (53%) exceeded the WHO standard 
of 10 μg As/L, and 56 (28%) were above 
Mexico’s MCL of 25 μg As/L (Figure 1).
Arsenic was detected in the urine of 
all women. Specifically, of the 200 women, 
DMAs were detected in all women’s urine, 
and 95% of the women had levels of iAs 
and MMAs that were above the LOD for 
these arsenicals (0.2 μg As/L and 0.1 μg 
As/L, respectively). Across the entire cohort, 
there was a significant positive relation-
ship between U-tAs and DW-iAs (r = 0.51, 
p < 0.0001) (Figure 1). The unadjusted sum 
of the urinary arsenicals (U-tAs) ranged from 
1.9 to 448.2 μg/L (mean, 35.5 μg As/L) 
(data not shown). To control for differen-
tial hydration, SG-adjusted concentrations 
of U-tAs were determined and ranged from 
4.3 to 319.7 μg As/L (mean, 37.5 μg As/L) 
(Table 1). The mean urinary concentrations 
of individual SG-adjusted arsenicals were 2.1, 
2.3, and 33.1 μg As/L for iAs, MMAs, and 
DMAs respectively (Table 1). This corresponds 
to the proportions of U-tAs comprising 6.1%, 
6.4%, and 87.6% for U-iAs, U-MMAs, and 
U-DMAs  respectively (Table 1).
DW-iAs and U-tAs levels were analyzed 
in relation to demographic characteristics. 
Most women (55%) reported that their 
primary drinking- and cooking-water source 
was from the tap (see Supplemental Material, 
Table S1). DW-iAs was higher (p < 0.0001) 
for those women who reportedly drank and 
cooked with municipally supplied water (i.e., 
tap) (medians of 23.3 and 18.1 μg As/L, 
respectively) than for those who reportedly 
Table 1. Selected demographic characteristics 
and levels of iAs in drinking water and urinary 
arsenicals of the participants of the BEAR study.
Characteristic
na (%) or mean,  
median [range]




< High school 50 (25.1)
High school 95 (47.7)
College 41 (20.6)
Post-college 13 (6.5)
Time living at residence (years) 20, 21 [1–41]
Smoking status
Nonsmokers 186 (93.0)


















Cesarean section 82 (41.0)
Gestational age (weeks)







All 3339, 3355 [1800–5120]
Male 3453, 3490 [2100–5120]*




Placental weight (g) 648, 640 [390–1070]
Newborn length (cm) 50, 50 [40–59]
Head circumference (cm) 35, 35 [31–38]
APGAR score 9, 9 [8–10]
Exposure measures
DW-iAs (μg As/L) 24.6, 13.0 [< LODb–236.0]
Urinary arsenicalsc
U-tAs (μg/L) 37.5, 23.3 [4.3–319.7]
U-iAs (μg/L) 2.1, 1.3 [0.14–23.0]
U-MMAs (μg/L) 2.3, 1.4 [0.12–18.2]
U-DMAs (μg/L) 33.1, 20.6 [1.4–292.5]
iAs (%) 6.1, 5.3 [0.77–45.1]
MMAs (%) 6.4, 6.0 [0.68–24.9]
DMAs (%) 87.6, 88.5 [32.7–96.7]
MMAs/iAs 1.2, 1.2 [0.13–5.5]
MMAs/DMAs 0.077, 0.069 [0.0072–0.68]
DMAs/MMAs 17.6, 14.6 [1.5–140.0]
MMAs + DMA/iAs 19.6, 18.1 [1.2–129.9]
aDifferences in n based on missing demographic data. 
bLOD for DW-iAs = 0.456 μg As/L. cAll urinary values 
were adjusted by SG. *Significant difference in means 
(p = 0.0003) between males and females.
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drank and cooked with bottled water 
(medians, 0.40 and 0.65 μg As/L, respec-
tively) (see Supplemental Material, Table S1). 
Similarly, U-tAs levels were higher in women 
who reportedly drank and cooked with 
municipally supplied water (means, 49.5 and 
42.9 μg As/L, respectively) than in those who 
drank and cooked with bottled water (means, 
22.9 and 18.5 μg As/L, respectively) (see 
Supplemental Material, Table S1). There were 
no statistically significant differences in U-tAs 
(see Supplemental Material, Table S1), U-iAs, 
or U-MMAs (data not shown) between the 
women who reported consuming seafood 
versus those who did not; however, women 
who consumed seafood had higher mean 
levels of U-DMAs than those who did not 
(42.5 μg As/L vs. 30.6 μg As/L, respectively). 
There was no statistical difference in U-tAs 
associated with a woman’s age; however, 
women with less than a high school education 
had significantly higher (p = 0.0173) U-tAs 
(mean, 47.70 g As/L) than women with a 
high school education (mean, 37.2 μg As/L), 
college (mean, 32.1 μg As/L), and greater 
than college education (mean, 19.4 μg As/L). 
There was no statistical difference in U-tAs 
based on residence status (e.g., urban or rural 
environment), smoking status, nor alcohol 
consumption (data not shown).
Relationship of DW-iAs and urinary 
arsenicals with birth outcomes. We used 
multivariable regression models to examine 
the relationships between nontransformed 
DW-iAs, SG-adjusted urinary levels, and 
proportions of iAs, MMAs, and DMAs 
and birth outcomes. The primary model 
(model 1) adjusted for maternal age, educa-
tion, smoking, and alcohol consumption, 
where all measured relationships represent 
analysis for a 1-unit change in exposure 
measures in association with birth outcomes/
measures. DW-iAs, U-tAs, U-DMAs, and 
percent iAs (%iAs) were not significantly 
associated with any of the birth outcomes 
(Table 2; see also Supplemental Material, 
Figure S1).
There was a significant negative relation-
ship between U-iAs and mean gestational age, 
with an estimated decrease of 0.069 weeks 
in gestational age for every 1-unit change 
in U-iAs [95% confidence interval (CI): 
–0.13, –0.0043, p = 0.03]. Similarly, there 
was an estimated decrease in mean newborn 
length of 0.16 cm in relationship to U-iAs 
(95% CI: –0.31, –0.019, p = 0.02). There was 
no significant association between U-iAs and 
birth weight, head circumference, placental 
weight, and APGAR score.
There was a significant negative asso-
ciation between U-MMAs and both mean 
gestational age (weeks) (β = –0.067; 95% CI: 
–0.13, –0.0092, p  = 0.02) and mean 
birth weight (grams) (β = –24.4; 95% CI: 
–46.8, –2.0, p = 0.03). There were no signifi-
cant associations between U-MMAs and 
mean head circumference, placental weight, 
and APGAR score. There was a significant 
negative relationship between %MMAs 
and mean birth weight, with an estimated 
24-g decrease in birth weight for every unit 
increase in %MMAs (95% CI: –45.6, –3.4, 
p = 0.02). There was no significant association 
with %MMAs and mean head circumference 
or APGAR score. Placental weight (grams) 
was also negatively associated with %MMAs 
(β = –9.8; 95% CI: –15.8, –3.8, p = 0.001) 
and positively associated with %DMAs 
(β = 3.5; 95% CI: 0.53, 6.5, p = 0.021).
Gestational age was included in model 2 
for comparative purposes (see Supplemental 
Material, Table S2). The inclusion of gesta-
tional age did influence the estimates, in 
general reducing the magnitude of the rela-
tionships observed in model 1. It is impor-
tant to consider, however, the potential 
role of gestational age as a mediator of birth 
outcomes. A sensitivity analysis that excluded 
seafood consumers (n = 43, 22% of all 
subjects) (model 3) showed consistent direc-
tions and significance of associations between 
exposure and metabolism indicators and birth 
outcomes, as observed with model 1 (see 
Supplemental Material, Table S2). Maternal 
urinary means of iAs and urinary arsenical 
proportions were not statistically different 
(p < 0.05) based on the sex of the infant (data 
not shown).
Discussion
The BEAR prospective pregnancy cohort in 
Mexico was established with a long-term goal 
of examining the effects of environmental 
exposure to iAs on the health of women and 
children and providing information to protect 
individuals from preventable exposure. The 
results of the present study demonstrate 
that pregnant women in the BEAR cohort 
are exposed to potentially harmful levels of 
iAs in their drinking water, ranging up to 
236 μg As/L. More than half of the samples 
exceeded the WHO-established safe drinking-
water guideline of 10 μg As/L. Elevated 
levels of arsenic have been observed in the 
drinking water of other exposed popula-
tions in Mexico. For instance, previously 
reported DW-iAs from central-eastern regions 
of Mexico ranged up to 1,504 μg As/L 
(Valenzuela et al. 2005) and up to 215 μg/L 
(Del Razo et al. 2011) in Hidalgo and 
Zimapán, respectively.
The  b iomoni tor ing  da ta  fur ther 
confirmed that pregnant women in the 
cohort are exposed to iAs, with SG-adjusted 
U-tAs ranging from 4.3 to 319.7 μg As/L. 
Levels of U-tAs were positively correlated 
with DW-iAs, consistent with drinking water 
being a source of iAs exposure in the BEAR 
cohort. The level of correlation between 
DW-iAs and U-tAs is similar to that of other 
iAs-exposed populations in Mexico (Del Razo 
et al. 2011). The levels of U-tAs in the 
BEAR cohort are generally lower than levels 
observed in pregnant women in Bangladesh 
(SG-adjusted medians, 23.3 μg As/L vs. 
80 μg As/L) (Vahter et al. 2006). However, 
the levels of U-tAs in this cohort are 
higher than levels observed in U.S. women 
(SG-adjusted mean, 37.5 μg As/L vs. creati-
nine adjusted geometric mean, 7.3 μg As/L) 
(Caldwell et al. 2009). The drinking-water 
samples from the present study were collected 
postpartum and represent a single exposure 
measure, so there is the potential that 
exposure varied over time. However, it has 
been demonstrated in prior research that iAs 
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levels in drinking water can vary little tempo-
rally (Slotnick et al. 2006; Steinmaus et al. 
2005). Additionally, the women in the study 
had lived in their current residences for at 
least 1 year, suggesting minimal variability in 
the source of iAs in drinking water and poten-
tially for iAs exposure as well. Taken together, 
the data from the present study highlight a 
new area of concern for elevated levels of iAs 
in drinking water in Mexico.
When analyzed for relationships to birth 
outcomes, overall DW-iAs and the sum of the 
urinary arsenicals (U-tAs) showed no signifi-
cant associations. Interestingly, there were 
significant relationships between levels and 
proportions of iAs, MMAs, and DMAs in 
maternal urine and selected birth outcomes. 
Specifically increases in U-iAs were associ-
ated with a lower means in gestational age 
and newborn length. Increases in U-MMAs 
were associated with a lower mean gestational 
age and birth weight. Similarly, increases in 
%MMAs were negatively associated with 
both lower mean placental weight and birth 
weight, with an estimated approximately 24-g 
decrease per unit increase in %MMAs. As 
total amounts of urinary arsenic as well as 
DMAs can be attributed in part to seafood 
consumption (Navas-Acien et al. 2011), a 
sensitivity analysis was performed on non-
seafood consumers. The point estimates 
between U-MMAs and %MMAs with 
birth weight were similar between seafood 
and non-seafood consumers, suggesting that 
these associations are not affected by seafood 
consumption. Although it is currently 
unknown whether the later-life health of 
the infants in this study will be influenced 
by the observed differences in birth weight, 
gestational age, and newborn length, these 
relationships will be important given global 
worldwide exposure to arsenic. Thus, follow-
up of these children is warranted as infants 
born with decreased gestational age, and 
changes to birth size are at risk for later life 
health effects.
Our data highlight the important finding 
that U-tAs alone was not significantly associ-
ated with birth outcomes, suggesting that the 
metabolism of iAs by a pregnant woman may 
be a better predictor of impact on both birth 
and placental weight, and newborn length 
than exposure level alone. Of note, the mean 
proportions of total urinary arsenicals from 
pregnant women in Gómez Palacio were 
approximately 6% for iAs, 6% for MMAs, 
and 88% for DMAs. These data indicate 
increased iAs methylation capacity (i.e., a shift 
to higher proportions of DMAs) relative to 
the proportions generally observed in exposed 
populations around the world, with observed 
ranges of approximately 10–20% for iAs, 
10–20% for MMAs, and 60–80% for DMAs 
(Vahter 2002). U-tAs and the individual 
urinary metabolites were measured once 
during pregnancy; nevertheless, all samples 
represented urinary collection during the end 
of pregnancy—immediately before delivery. 
Therefore, shifts in iAs metabolism that occur 
differentially between trimesters of pregnancy 
(Hopenhayn et al. 2003a) should not influ-
ence these findings. The results in the present 
study highlight a relative increase in propor-
tions of DMAs, consistent with other studies 
where later stages of pregnancy were associ-
ated with proportions of DMAs exceeding 
80% (Concha et al. 1998; Gardner et al. 
2011, 2012; Hopenhayn et al. 2003b). It has 
been suggested that higher DMAs:MMAs 
ratios indicate an increased iAs methylation 
capacity and may have a protective effect 
for both mother and fetus, because it could 
reflect reduced levels of the highly toxic triva-
lent MMAsIII (Vahter 2002, 2009).
An inverse relationship between DW-iAs 
and birth weight has been observed previously 
(Hopenhayn et al. 2003a; Yang et al. 2003) 
as well as U-tAs and size at birth (Rahman A 
et al. 2009). However, some studies have 
found no association between prenatal iAs 
exposure and size at birth (Kwok et al. 2006; 
Myers et al. 2010). These differences may be 
attributed to variation in study design and 
methodology (e.g., bias, misclassification, 
and/or random error), as well as inherent 
differences in population characteristics (e.g., 
exposure/consumption of iAs contaminated 
drinking water, genetic polymorphisms, and 
nutritional factors). Furthermore, studies that 
do not address interindividual differences 
in metabolism to iAs would not capture the 
associations observed in the present study. To 
our knowledge, the results from the BEAR 
cohort are the first to demonstrate that levels 
and proportions of MMAs and levels of U-iAs 
in maternal urine are associated with poorer 
birth outcomes. These findings support 
a growing body of literature detailing that 
Table 2. Multivariable regression analysesa between a 1-unit increase in exposure and metabolism indicators (DW-iAs, SG-adjusted U-tAs, U-iAs, U-MMAs, 
U-DMAs, %iAs, %MMAs, and %DMAs) and birth outcomes.
Variable Gestational age (weeks) Birth weight (g) Newborn length (cm) Head circumference (cm) Placental weight (g) APGAR score
DW-iAs
β (CI) –0.0025 (–0.0065, 0.0061) –0.1 (–1.7, 1.4) –0.0051 (–0.014, 0.0038) –0.0026 (–0.0077, 0.0026) 0.12 (–0.32, 0.57) 0 (–0.0005, 0.0005)
p-Value 0.22 0.89 0.26 0.33 0.58 0.98
U-tAs
β (CI) –0.0036 (–0.0075, 0.003) –0.58 (–2.1, 0.93) –0.0055 (–0.014, 0.0033) –0.0022 (–0.0074, 0.0029) 0.31 (–0.14, 0.76) 0 (–0.0004, 0.0005)
p-Value 0.07 0.44 0.22 0.39 0.17 0.85
U-iAs
β (CI) –0.069 (–0.13, –0.0043) –21.7 (–46.8, 3.4) –0.16 (–0.31, –0.019) –0.061 (–0.15, 0.030) 0.73 (–7.1, 8.5) –0.0013 (–0.0097,0.0072)
p-Value 0.03* 0.09 0.02* 0.18 0.85 0.76
U-MMAs
β (CI) –0.067 (–0.13, –0.0092) –24.4 (–46.8, –2.0) –0.11 (–0.24, 0.018) –0.067 (–0.14, 0.011) –1.3 (–8.0, 5.5) 0.0004 (–0.0069, 0.0070)
p-Value 0.02* 0.03* 0.08 0.09 0.71 0.91
U-DMAs
β (CI) –0.0037 (–0.0081, 0.0006) –0.49 (–2.2, 1.2) –0.0054 (–0.015, 0.0043) –0.0021 (–0.0079, 0.0036) 0.38 (–0.11, 0.88) 0.0001 (–0.0005, 0.0006)
p-Value 0.09 0.56 0.27 0.46 0.12 0.82
%iAs
β (CI) –0.0006 (–0.043, 0.042) –6.4 (–22.9, 10.0) –0.054 (–0.15, 0.041) 0.01 (–0.044, 0.065) –3.2 (–7.9, 1.6) –0.0002 (–0.0054, 0.0049)
p-Value 0.97 0.44 0.26 0.71 0.18 0.92
%MMAs
β (CI) –0.043 (–0.098, 0.012) –24.5 (–45.6, –3.4) –0.082 (–0.21, 0.041) –0.03 (–0.10, 0.041) –9.8 (–15.8, –3.8) 0.011 (–0.0056, 0.078)
p-Value 0.12 0.02* 0.19 0.41 0.001* 0.73
%DMAs
β (CI) 0.011 (–0.017, 0.38) 8.9 (–1.5, 19.3) 0.041 (–0.020, 0.10) 0.0025 (–0.032, 0.037) 3.5 (0.53, 6.5) –0.0001 (–0.0034, 0.003)
p-Value 0.44 0.09 0.17 0.88 0.02* 0.93
aModel 1 was adjusted for the following covariates: maternal age, education, smoking, and alcohol consumption. *Association between birth outcomes and arsenic exposure 
 indicators, p < 0.05.
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urinary proportions of MMAs are positively 
correlated with detrimental health effects of 
iAs (reviewed by Tseng 2007a).
Although the data in the present study 
suggest an association between maternal 
methylation of iAs and infant birth weight, 
gestational age, and newborn length, this 
study is not without limitations. In addition 
to iAs exposure and metabolism, other factors 
that may influence birth outcomes include 
 coexposure to other contaminants, gestational 
age, and maternal genotype. Additionally, 
residual confounding may remain based on 
maternal SES and potentially dietary sources 
of iAs. Together these complex factors may 
influence the relationships between iAs 
exposure during pregnancy and newborn 
health outcomes, and should be examined in 
larger cohort studies. It will be important in 
future research to examine the links between 
early-life exposure to iAs and postnatal devel-
opment in the children through prospec-
tive analysis. Taken together, these data will 
enable a better understanding of the etiology 
of poorer birth outcomes associated with iAs 
exposure in early life.
Conclusions
This study suggests three major findings. 
First, more than half of the drinking-water 
samples tested in Gómez Palacio exceeded 
the WHO’s guidelines for acceptable 
limits of iAs in drinking water, indicating 
that women drinking municipal water are 
at risk for elevated exposure to iAs. Second, 
biomonitoring data confirmed that many 
pregnant women had elevated levels of iAs 
in their urine. Third, individual differences 
in iAs metabolism in pregnant women were 
associated with birth outcomes. Specifically, 
elevated levels and proportions of MMAs 
in maternal urine were negatively associated 
with birth weight and gestational age, and 
urinary iAs was negatively associated with 
gestational age and newborn length. Given 
that these exposures to elevated iAs are 
occurring during pregnancy, there may also 
be concerns about later-life health effects for 
the children of the cohort. The results of this 
study suggest that a follow-up examination of 
the impacts of iAs exposure on the health of 
the women and their children is warranted.
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